CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Horizon Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Horizon Therapeutics Inc
2000 Sierra Point Pkwy Ste 400
Phone: (650) 745-7802p:650 745-7802 BRISBANE, CA  94005-1849  United States Ticker: HPTXHPTX
This company was Merged or Acquired on 5/7/2015.
This company ceased filing statements with the SEC on 5/18/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Hyperion Therapeutics Inc. is a commercial biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company’s products include RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients with urea cycle disorders (UCDs). The Company has completed its Phase III trials. BUPHENYL Tablets for oral administration and BUPHENYL Powder for oral, nasogastric, or gastrostomy tube administration are indicated as adjunctive therapy in the chronic management with UCDs involving deficiencies of CPS, OTC and AS. BUPHENYL is indicated for neonatal-onset deficiency and also indicated for late-onset disease with a history of hyperammonemic encephalopathy.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201512/31/2014YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board James I.Healy 49 7/1/2009 1/1/2006
President, Chief Executive Officer, Director Donald J.Santel 53 3/1/2007
Chief Financial Officer Jeffrey S.Farrow 52 8/1/2013
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Andromeda Biotech Ltd.
BUPHENYL
HPTX
5 additional Business Names available in full report.

General Information
Number of Employees: 80 (As of 12/31/2014)
Outstanding Shares: 20,976,592 (As of 4/30/2015)
Shareholders: 25
Stock Exchange: NASD
Federal Tax Id: 611512713
Fax Number: (650) 871-7029


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023